Preview

Translational Medicine

Advanced search

New technologies (photodynamic therapy and specific antitumor immunotherapy) in treatment of patients with malignant supratentorial astrocytic tumors. Evaluation of remote results

https://doi.org/10.18705/2311-4495-2015-0-2-3-103-112

Abstract

Background. Glial tumors are the most common tumors of the brain, with their malignant form - anaplastic astrocytoma and glioblastoma exceed 50 % and accounting for only 2 % of all tumors in adults, take fourth place in the structure of cancer mortality. Objective: To determine the effectiveness of new technologies of treatment of malignant glial tumors (photodynamic therapy and specific antitumor immunotherapy based on autologous dendritic cells). Design and Methods: We consider the results of treatment 356 patients with malignant glial tumors. Depending on the treatment, 5 groups were formed, 3 of which, in addition to standard procedures (surgery, radiotherapy, chemotherapy) photodynamic and/or immunotherapy were used. Results: when used in addition to standard methods, photodynamic therapy in patients with anaplastic astrocytoma average life expectancy and the median survival were 50.8 months and 35 months, glioblastomas - 47.9 months and 30 months, giant cell glioblastomas - 34 months and 34 months, that is higher than in the groups of patients with only standard methods of treatment. Application of 3 or more courses of immunotherapy also improves life expectancy and median survival of these patients 50.22 months and 32 months in patients with anaplastic astrocytomas, and 23.72, and 24 months in patients with glioblastomas. Conclusions: The highest average life expectancy and the median survival among patients with anaplastic astrocytomas, glioblastomas and giantcell glioblastomas in our study were achieved in patients in which treatment in addition to standard therapies (surgery, radiotherapy, chemotherapy) was added by photodynamic therapy. When managed with immunotherapy additionally to standard methods, life expectancy increased only if more than 3 courses were used.

About the Authors

V. E. Oljushin
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


D. M. Rostovcev
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


G. V. Papajan
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


M. V. Filatov
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


T. N. Fadeeva
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


K. S. Burnin
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


V. Ja. Kalmens
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


S. A. Melchenko
Divisions of Polenov Russian Scienific Research Institute of Neurosurgery
Russian Federation


References

1. Ataman F, Poortmans P, Stupp R. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur j cancer. 2004. - Vol. 40. P. 1724-1730.

2. Chang, S. M., Parney I. F., Huang W. Patterns of care for adults with newly diagnosed malignant glioma, JAMA. 2005. Vol. 293. P. 557-564.

3. Friedman, H. S., Bigner D. D. Glioblastoma multiforme and the epidermal growth factor receptor. New engl j med. 2005. Vol. 353. Р. 1997-1999.

4. Glioblastoma. Molecular mechanism of pathogenesis and current therapeutic strategies. S. K. Ray Editor Springer 2010. Р. 431.

5. Gulley, J. L., Drake C. G. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin cancer res. 2011. Vol. 17, № 12. P. 3884-3891.

6. Louis, D. N., Ohgaki H., Wiestler O. D. WHO Classification of Tumours of the Central Nervous System. - Lyon, France: International Agency for Research on Cancer, 2007. p. 312.

7. Гельфонд, М. Л. Возможности фотодинамической терапии в онкологической практике. Физ. мед. 2005. Т. 15, № 2. - С. 33-37. [Gel’fond, M. L. Vozmozhnosti fotodinamicheskoj terapii v onkologicheskoj praktike. Fiz. med. 2005. T.15, № 2. - S. 33-37. In Russian]

8. Глиомы головного мозга (современное состояние проблемы и пути дальнейших поисков).Под. ред. Ю. А. Зозули. Киев, 2007. 636 с. [Gliomy golovnogo mozga (sovremennoe sostojanie problemy i puti dal’nejshih poiskov).Pod. red. Ju. A. Zozuli. Kiev, 2007. 636 s. In Russian]

9. Горяйнов С. А., Потапов А. А., Лощенов В. Б. Флуоресцентная навигация и лазерная спектроскопия в хирургии глиом головного мозга. - М.: Медиа Сфера, 2014. 152 с. [Gorjajnov, S.A., Potapov A.A., Loshhenov V. B. Fluorescentnaja navigacija i lazernaja spektroskopija v hirurgii gliom golovnogo mozga. - M.: Media Sfera, 2014. 152 s. In Russian]

10. Олюшин, В. Е., Комфорт А. В., Улитин А. Ю. Новый способ фотодинамической терапии в комплексном лечении глиальных опухолей головного мозга. Рос. биотер. журн. 2007. Т. 6, № 1. С. 23. [Oljushin, V. E., Komfort A. V., Ulitin A.Ju. Novyj sposob fotodinamicheskoj terapii v kompleksnom lechenii glial’nyh opuholej golovnogo mozga. Ros. bioter. zhurn. 2007. T. 6, № 1. S. 23. In Russian]

11. Олюшин, В. Е., Филатов М. В., Улитин А. Ю., Бажанов С. П. Специфическая противоопухолевая иммунотерапия на основе дендритных клеток в комплексном лечении больных злокачественными церебральными глиомами. С. Петербург, 2012. 211 с. [Oljushin, V. E., Filatov M. V., Ulitin A.Ju., Bazhanov S. P. Specificheskaja protivoopuholevaja immunoterap ija na osnove dendritnyh kletok v kompleksnom lechenii bol’nyh zlokachestvennymi cerebral’nymi gliomami. S. Peterburg, 2012. 211 s. In Russian] 1 3. Олюшин, В. Е. Способ выбора нейроонкологических больных для иммунотерапии. Патент на изобретение РФ № 2297632 20 апреля 2007 [Oljushin, V. E. Sposob vybora nejroonkologicheskih bol’nyh dlja immunoterapii. Patent na izobretenie RF № 2297632 20 aprelja 2007. In Russian]

12. Олюшин, В. Е. Способ лечения глиальных опухолей головного мозга супратенториальной локализации. Патент на изобретение РФ № 2551241 16 апреля 2015 [Oljushin, V. E. Sposob lechenija glial’nyh opuholej golovnogo mozga supratentorial’noj lokalizacii. Patent na izobretenie RF № 2551241 16 aprelja 2015. In Russian]

13. Олюшин, В. Е. Способ лечения злокачественных опухолей головного мозга. Патент на изобретение РФ № 2192263 10 ноября 2002 [Oljushin, V. E. Sposob lechenija zlokachestvennyh opuholej golovnogo mozga. Patent na izobretenie RF № 2192263 10 nojabrja 2002. In Russian]

14. Олюшин, В. Е. Способ фотодинамической терапии для лечения глиальных опухолей больших полушарий мозга. Патент на изобретение РФ № 2318542 10 марта 2008 [Oljushin, V. E. Sposob fotodinamicheskoj terapii dlja lechenija glial’nyh opuholej bol’shih polusharij mozga. Patent na izobretenie RF № 2318542 10 marta 2008. In Russian]

15. Улитин, А. Ю., Мацко Д. Е., Олюшин В. Е. Нейроэпителиальные опухоли головного мозга С. Петербург, 2014. 443 с. [Ulitin, A.Ju., Macko D. E., Oljushin V. E. Nejrojepitelial’nye opuholi golovnogo mozga S. Peterburg, 2014. 443 s. In Russian]


Review

For citations:


Oljushin V.E., Rostovcev D.M., Papajan G.V., Filatov M.V., Fadeeva T.N., Burnin K.S., Kalmens V.J., Melchenko S.A. New technologies (photodynamic therapy and specific antitumor immunotherapy) in treatment of patients with malignant supratentorial astrocytic tumors. Evaluation of remote results. Translational Medicine. 2015;(2-3):103-112. (In Russ.) https://doi.org/10.18705/2311-4495-2015-0-2-3-103-112

Views: 878


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-4495 (Print)
ISSN 2410-5155 (Online)